This study is looking at how immunosuppression treatment affects individuals with certain types of interstitial lung disease (ILD), which is a group of lung conditions that cause scarring of the lungs. Researchers will use advanced imaging techniques, specifically [68Ga]CBP8 PET scans and Gadoterate Meglumine DCE-MRI scans, to measure active collagen deposition (scarring) and tissue injury. The goal is to see if immunosuppression treatment changes these measurements over 12 weeks. You may be able to join if you are 18-80 years old, have chronic hypersensitivity pneumonitis, connective tissue-associated ILD, or undifferentiated ILD, and are starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and/or prednisone. The study aims to enroll 15 participants, but its current status is unclear.

Study design

This is an interventional study planning to enroll 15 participants. It will assess the effects of immunosuppression treatment on specific imaging measurements.

What's involved

Participants will undergo [68Ga]CBP8 PET and DCE-MRI scans before starting treatment and again 12 weeks later. They will also receive single intravenous injections of [68Ga]CBP8 and Gadoterate Meglumine during these imaging procedures.

Compensation

Not stated in the trial record.

Follow-up

Measurements will be taken from baseline to 12 weeks after treatment initiation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.